Article Text

Download PDFPDF
CASE REPORT
What are the odds? Prostate metastases to ureter and peritoneum
  1. Caren van Roekel1,
  2. Trudy G N Jonges2,
  3. Tycho M T W Lock3
  1. 1Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
  2. 2Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
  3. 3Department of Urology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
  1. Correspondence to Caren van Roekel, j.vanroekel{at}umcutrecht.nl

Summary

In patients with prostate cancer, metastases mostly develop in bone, lung, liver, pleura and adrenal glands. Prostate carcinoma metastases to the ureter are very rare, and the peritoneum is an even rarer site of prostate metastases. We present two cases of ureteral metastases of prostate cancer, of which one patient also developed malignant ascites and peritoneal metastases. An overview of the literature on these metastatic sites is also provided. Both patients presented with hydronephrosis and a ureteral mass. Biopsies of the masses were taken, which showed the presence of prostate carcinoma metastases. The first patient was treated with chemotherapy but was diagnosed with progressive disease and died 3 years later. The second patient was diagnosed with pathology-confirmed peritoneal metastases 8 months later. He died 2 years after presentation with hydronephrosis.

  • cancer intervention
  • prostate cancer
  • urological cancer
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors All authors have read, applied changes and approved the final manuscript. CvR has written the manuscript and performed the literature search. TGNJ has provided the pathological images and has done the pathological analysis. TMTWTL has collected the patient cases, provided feedback on the manuscript and contributed in writing the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Next of kin consent obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.